락토바실루스 가세리 관련 헬리코박터 파일로리 감염
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.3건의 RCT에서 락토바실루스 가세리 LG21이 헬리코박터 파일로리 균수를 억제하고 표준 삼중요법과 병용 시 근절률을 개선하는 것으로 나타났습니다. GERD 증상도 개선합니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
3건의 RCT에서 락토바실루스 가세리 LG21이 헬리코박터 파일로리 균수를 억제하고 표준 삼중요법과 병용 시 근절률을 개선하는 것으로 나타났습니다. GERD 증상도 개선합니다.
Key Study Findings
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
효과: None
None
대상 집단: AGS gastric epithelial cells and mouse model
In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None
vs: CagA-expressing AGS cells without L. gasseri
Outcome: Suppression of CagA phosphorylation (hummingbird)
효과: None
None
대상 집단: Human gastric AGS cell line with H. pylori CagA
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: Cancer patients
Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None
vs: None
Outcome: H. pylori abundance reduction
효과: None
None
대상 집단: H. pylori-infected C57BL/6 mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
효과: None
None
대상 집단: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
연구
350
참여자
↑
Positive
B
등급
Referenced Papers
International journal of …
2025
4 인용
International journal of …
2025
Microbial pathogenesis
2024
8 인용
Helicobacter
2024
5 인용
International journal of …
2022
59 인용
BMC microbiology
2022
28 인용
Food & function
2022
19 인용
Probiotics and antimicrobial …
2021
30 인용
Comparative immunology, microbiology …
2019
72 인용
Frontiers in immunology
2019
61 인용
Frontiers in microbiology
2019
31 인용
BMJ open gastroenterology
2019
14 인용
Digestion
2017
67 인용
Gastroenterology research and …
2016
38 인용
Helicobacter
2015
26 인용
PloS one
2014
171 인용
Frontiers in microbiology
2014
78 인용
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 인용
Journal of gastroenterology …
2012
76 인용
Journal of food …
2012
56 인용
Journal of clinical …
2012
37 인용
Journal of dairy …
2010
43 인용
Journal of medicinal …
2010
19 인용
Probiotics and antimicrobial …
2010
9 인용
Helicobacter
2009
48 인용
Cellular microbiology
2006
50 인용
Journal of gastroenterology …
2006
41 인용
Letters in applied …
2006
26 인용
Journal of pharmacological …
2004
58 인용
Journal of gastroenterology …
2003
77 인용
Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children.
Other
The Journal of …
2002
31 인용
The Journal of …
2001
309 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| 1 g | -- | Positive | -- |
권장 복용 시간: Before meals or with meals; yogurt form taken with food
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 락토바실루스 가세리 help with 헬리코박터 파일로리 감염?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that 락토바실루스 가세리 may support 헬리코박터 파일로리 감염 management. Our evidence grade is B (Good Evidence).
How much 락토바실루스 가세리 should I take for 헬리코박터 파일로리 감염?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 락토바실루스 가세리?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 락토바실루스 가세리 and 헬리코박터 파일로리 감염?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 헬리코박터 파일로리 감염
락토바실루스 가세리 다른 건강 상태에 대한 근거
References
- [1] Rajesh K Gupta et al.. Int J Mol Sci. 2025. Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction. doi:10.3390/ijms26146718 PubMed
- [2] Tanvi Somiah et al.. Int J Med Microbiol. 2025. Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in gastric host cells. doi:10.1016/j.ijmm.2025.151694 PubMed
- [3] Zahra Sadeghloo et al.. Microb Pathog. 2024. The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of Helicobacter pylori in gastric epithelial … doi:10.1016/j.micpath.2024.106559 PubMed
- [4] Marine Jauvain et al.. Helicobacter. 2024. Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection. doi:10.1111/hel.13108 PubMed
- [5] Fen Wu et al.. Int J Cancer. 2022. Oral and gastric microbiome in relation to gastric intestinal metaplasia. doi:10.1002/ijc.33848 PubMed
- [6] Tran Thi Dieu Thuy et al.. BMC Microbiol. 2022. Anti-Helicobacter pylori activity of potential probiotic Lactiplantibacillus pentosus SLC13. doi:10.1186/s12866-022-02701-z PubMed
- [7] Yuyang Zhao et al.. Food Funct. 2022. Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice. doi:10.1039/d2fo02034c PubMed
- [8] Mahdieh Yarmohammadi et al.. Probiotics Antimicrob Proteins. 2021. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected … doi:10.1007/s12602-020-09721-z PubMed
- [9] Majid Eslami et al.. Comp Immunol Microbiol Infect Dis. 2019. Are probiotics useful for therapy of Helicobacter pylori diseases? doi:10.1016/j.cimid.2019.02.010 PubMed
- [10] Hanna G Gebremariam et al.. Front Immunol. 2019. Lactobacillus gasseri Suppresses the Production of Proinflammatory Cytokines in Helicobacter pylori-Infected Macrophages by Inhibiting the Expression of ADAM17. doi:10.3389/fimmu.2019.02326 PubMed
- [11] Fanglei Zuo et al.. Front Microbiol. 2019. Role of Sortase A in Lactobacillus gasseri Kx110A1 Adhesion to Gastric Epithelial Cells and Competitive Exclusion of Helicobacter pylori. doi:10.3389/fmicb.2019.02770 PubMed
- [12] Yasuhiro Koga et al.. BMJ Open Gastroenterol. 2019. Probiotic L. gasseri strain (LG21) for the upper gastrointestinal tract acting through improvement of indigenous microbiota. doi:10.1136/bmjgast-2019-000314 PubMed
- [13] Toshihiro Ohtsu et al.. Digestion. 2017. The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study. doi:10.1159/000479000 PubMed
- [14] Atsushi Takagi et al.. Gastroenterol Res Pract. 2016. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. doi:10.1155/2016/7490452 PubMed
- [15] Hidenori Matsui et al.. Helicobacter. 2015. Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of … doi:10.1111/hel.12203 PubMed
- [16] Yini Dang et al.. PLoS One. 2014. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. doi:10.1371/journal.pone.0111030 PubMed
- [17] Susana Delgado et al.. Front Microbiol. 2014. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric … doi:10.3389/fmicb.2014.00766 PubMed
- [18] Kurt Selle et al.. FEMS Microbiol Rev. 2013. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health. doi:10.1111/1574-6976.12021 PubMed
- [19] Ryuzo Deguchi et al.. J Gastroenterol Hepatol. 2012. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. doi:10.1111/j.1440-1746.2011.06985.x PubMed
- [20] Xiaohua Chen et al.. J Food Sci. 2012. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. doi:10.1111/j.1750-3841.2011.02498.x PubMed
- [21] Shigeru Fujimura et al.. J Clin Microbiol. 2012. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. doi:10.1128/JCM.06262-11 PubMed
- [22] X Chen et al.. J Dairy Sci. 2010. In vitro screening of lactobacilli with antagonistic activity against Helicobacter pylori from traditionally fermented foods. doi:10.3168/jds.2010-3449 PubMed
- [23] Yuko Kato-Mori et al.. J Med Food. 2010. Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. doi:10.1089/jmf.2010.1137 PubMed
- [24] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
- [25] Surasak Boonyaritichaikij et al.. Helicobacter. 2009. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. doi:10.1111/j.1523-5378.2009.00675.x PubMed
- [26] Takeshi Shimosato et al.. Cell Microbiol. 2006. Strong immunostimulatory activity of AT-oligodeoxynucleotide requires a six-base loop with a self-stabilized 5'-C...G-3' stem structure. doi:10.1111/j.1462-5822.2005.00640.x PubMed
- [27] Akira Tamura et al.. J Gastroenterol Hepatol. 2006. Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. doi:10.1111/j.1440-1746.2006.04318.x PubMed
- [28] S Fujimura et al.. Lett Appl Microbiol. 2006. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. doi:10.1111/j.1472-765X.2006.02017.x PubMed
- [29] Masayuki Uchida et al.. J Pharmacol Sci. 2004. Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against [correction of agaisnt] acute gastric lesion and antral ulcer in rats. doi:10.1254/jphs.fpj04027x PubMed
- [30] Atsushi Ushiyama et al.. J Gastroenterol Hepatol. 2003. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. doi:10.1046/j.1440-1746.2003.03102.x PubMed
- [31] Toshiaki Shimizu et al.. J Antimicrob Chemother. 2002. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. doi:10.1093/jac/dkf157 PubMed
- [32] I Sakamoto et al.. J Antimicrob Chemother. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. doi:10.1093/jac/47.5.709 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.